News
The FDA has approved Cabometyx (cabozantinib) for previously treated, unresectable, locally advanced or metastatic, well-differentiated neuroendocrine tumors.
The approval was based on the results of the phase 3 CABINET study, which compared cabozantinib to a placebo in patients with advanced pancreatic neuroendocrine tumors and advanced extrapancreatic ...
Woese Institute for Genomic Biology, University of Illinois at Urbana−Champaign, Urbana, Illinois 61801, United States Pancreatic neuroendocrine ... activator PAC-1 enhances PNET cell death in cell ...
MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...
MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced ...
for patients with previously treated advanced neuroendocrine tumors, offering a new standard of care for this patient group, according to a press release from the Dana-Farber Cancer Institute.
well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET). The approval is supported by data from the phase 3 CABINET trial.
Median PFS among 99 patients with pNET who were randomized 2:1 to receive cabozantinib or ... progression…regardless of primary tumor site and grade. Sharon Worcester, MA, is an award-winning ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX ® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 ...
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of ...
After canceling a planned advisory committee meeting, the FDA has approved Exelixis’ Cabometyx for neuroendocrine ... Cancer Network updated its guidelines to recommend Cabometyx as a category 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results